Using regulatory data
In my recent post I expressed frustration with the direction of travel of rapid reviews and one thing I highlighted was the lack of work on using regulatory data. This prompted two responses highlighting two separate papers: How to use FDA drug approval documents for evidence syntheses, BMJ 2018 Practical guidance for using multiple data sources in systematic reviews and meta‐analyses (with examples from the … Continue reading Using regulatory data